Comparative study on hemato- and nephrotoxicity profile of weekly versus every 3-weekly cisplatin dosage during induction chemotherapy in locally advanced head neck squamous cell carcinoma

The Egyptian Journal of Otolaryngology

Table 1 Characteristics of LA-SCCHN patients receiving weekly (group A) and every 3-weekly (group B) cisplatin dose

Patient characteristics	Weekly dose cisplatin (mean dose: 30 mg/m²) (n = 15)	Every 3-week dose cisplatin (mean dose: 100 mg/m²) (n = 15)
Median age (years)	49.1 ± 5.9	48.3 ± 4.8
Male	12(80%)	12(80%)
Female	3(20%)	3(20%)
Mean BSA	1.6	1.5
Site
Oral cavity	1(6.7%)	2(13.3%)
Oropharynx	5(33.3%)	6(40%)
Pharynx	3(20%)	4(26.6%)
Larynx	3(20%)	1(6.7%)
Hypopharybx	2(13.3%)	1(6.7%)
Esophagus	1(6.7%)	1(6.7%)
Stage
Stage I	0	0
Stage II	3(20%)	1(6.7%)
Stage III	10(66.6%)	11(73.3%)
Stage IV	2(13.3%)	3(20%)
Total mean cisplatin dose	170 mg/m²	220.32 mg/m²
Total mean 5-FU dose	4672 mg	4620 mg